ResMed Inc. reported a strong financial performance for the fiscal year ending June 30, 2025, with net revenues reaching $5.146 billion, a 10% increase from $4.685 billion in the previous year. The company's gross profit also saw a significant rise, climbing to $3.055 billion, up 15% from $2.655 billion in fiscal 2024. Net income for the year was $1.401 billion, translating to diluted earnings per share of $9.51, compared to $1.021 billion and $6.92 per share in the prior year. This growth was attributed to increased demand for both devices and masks in the Sleep and Breathing Health segment, as well as a steady performance in the Residential Care Software segment, which generated $641 million in revenue, a 10% increase from the previous year.
The company experienced notable operational changes, including the acquisition of VirtuOx, a software-enabled independent diagnostic testing facility, which was completed in May 2025. This acquisition is expected to enhance ResMed's capabilities in providing comprehensive sleep and respiratory health solutions. Additionally, ResMed launched its home sleep apnea test, NightOwl, across the U.S. in April 2025, further expanding its product offerings. The company also reported a workforce of over 10,600 employees, with a focus on maintaining a diverse and inclusive environment to support its growth strategy.
Geographically, ResMed's revenue growth was consistent across regions, with the U.S., Canada, and Latin America contributing $2.998 billion, a 10% increase from the previous year. The combined revenue from Europe, Asia, and other markets also rose by 9% to $1.507 billion. The company noted that its cloud-connected devices are now used by over 30 million patients, with more than 10 million registered on its myAir platform, indicating strong product adoption and engagement metrics.
Looking ahead, ResMed remains optimistic about its growth trajectory, driven by increasing awareness of sleep apnea and chronic obstructive pulmonary disease (COPD), as well as the ongoing shift towards home-based healthcare solutions. The company plans to continue investing in research and development, with $331 million allocated in fiscal 2025, representing 6.4% of net revenues. ResMed's management anticipates that these strategic initiatives, along with its robust product pipeline, will position the company well for future growth in the evolving healthcare landscape.
About RESMED INC
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.